{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:03:16Z","timestamp":1787655796529,"version":"build-2736575974"},"reference-count":46,"publisher":"BMJ","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gut"],"accepted":{"date-parts":[[2011,11,16]]},"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the efficacy of acotiamide, an acetylcholinesterase inhibitor, in patients with functional dyspepsia (FD) in a 4-week trial<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multicentre, randomised, placebo-controlled, parallel-group, phase III trial was carried out, in which patients with FD received 100\u2005mg of acotiamide or placebo three times a day for 4\u2005weeks, with 4\u2005weeks post-treatment follow-up. The primary efficacy end points were global assessment of overall treatment efficacy (OTE) and elimination rate of all three meal-related symptoms (postprandial fullness, upper abdominal bloating and early satiation), as derived from daily diaries. Secondary efficacy end points were individual symptom scores and quality of life. Adverse events were monitored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>52.2% of those receiving acotiamide and 34.8% in the placebo group (p&lt;0.001) were classified as responders according to a global assessment of OTE. Over 4\u2005weeks, the elimination rate for all three meal-related symptoms was 15.3% among patients receiving acotiamide compared with 9.0% in the placebo group (p=0.004). The significant benefit of acotiamide over placebo in OTE and elimination rate was maintained during the 4\u2005week post-treatment follow-up. All other secondary efficacy end points, including quality of life, were significantly improved with 100\u2005mg of acotiamide as compared with placebo. The number needed to treat was 6 for OTE and 16 for symptom elimination rate. The incidence of adverse events was similar between the acotiamide group and placebo group and no significant cardiovascular effects due to treatment were seen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Over 4\u2005weeks, acotiamide significantly improved symptom severity and eliminated meal-related symptoms in patients with FD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">http:\/\/ClinicalTrials.gov<\/jats:ext-link>\n                      number,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00761358\">NCT00761358<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2011-301454","type":"journal-article","created":{"date-parts":[[2011,12,10]],"date-time":"2011-12-10T01:01:16Z","timestamp":1323478876000},"page":"821-828","source":"Crossref","is-referenced-by-count":205,"title":["A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia"],"prefix":"10.1136","volume":"61","clinical-trial-number":[{"clinical-trial-number":"nct00761358","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Kei","family":"Matsueda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Hongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Tack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youichi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2011,12,9]]},"reference":[{"key":"2025121301475126000_61.6.821.1","unstructured":"Drossman DA Corazziari E Delvaux M . Rome III: The Functional Gastrointestinal Disorders. 3rd edn. McLean, VA: Degnon Associates, Inc., 2006."},{"key":"2025121301475126000_61.6.821.2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/003655299750025237","article-title":"Three-Month Prevalence Rates of Gastrointestinal Symptoms and the Influence of Demographic Factors: Results from the Domestic\/International Gastroenterology Surveillance Study (DIGEST)","volume":"231","author":"Stanghellini","year":"1999","journal-title":"Scand J Gastroenterol Suppl"},{"key":"2025121301475126000_61.6.821.3","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2001.02454.x"},{"key":"2025121301475126000_61.6.821.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-009-0168-x"},{"key":"2025121301475126000_61.6.821.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2008.05410.x"},{"key":"2025121301475126000_61.6.821.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.03.003"},{"key":"2025121301475126000_61.6.821.7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.09.020"},{"key":"2025121301475126000_61.6.821.8","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.059"},{"key":"2025121301475126000_61.6.821.9","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2011.562890"},{"key":"2025121301475126000_61.6.821.10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0022-3565(24)39036-6","article-title":"Z-338 facilitates acetylcholine release from enteric neurons due to blockade of muscarinic autoreceptors in guinea pig stomach","volume":"294","author":"Ogishima","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"2025121301475126000_61.6.821.11","doi-asserted-by":"publisher","DOI":"10.1540\/jsmr.36.69"},{"key":"2025121301475126000_61.6.821.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2008.01135.x"},{"key":"2025121301475126000_61.6.821.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2009.01449.x"},{"key":"2025121301475126000_61.6.821.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2009.01261.x"},{"key":"2025121301475126000_61.6.821.15","doi-asserted-by":"crossref","first-page":"A157","DOI":"10.1016\/S0016-5085(08)60732-5","article-title":"A novel acetylcholine esterase inhibitor acotiamide hydrochloride (YM443) in functional dyspepsia: efficacy in a randomized, double-blind, placebo-controlled dose ranging trial","volume":"134","author":"Talley","year":"2008","journal-title":"Gastroenterology"},{"key":"2025121301475126000_61.6.821.16","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.11.031"},{"key":"2025121301475126000_61.6.821.17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04566.x"},{"key":"2025121301475126000_61.6.821.18","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90080-4"},{"key":"2025121301475126000_61.6.821.19","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0002-9270(00)02314-5","article-title":"Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis","volume":"96","author":"Veldhuyzen van Zanten","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"2025121301475126000_61.6.821.20","first-page":"660","article-title":"Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials","volume":"91","author":"Veldhuyzen van Zanten","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"2025121301475126000_61.6.821.21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7344.1012"},{"key":"2025121301475126000_61.6.821.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02466.x"},{"key":"2025121301475126000_61.6.821.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00751.x"},{"key":"2025121301475126000_61.6.821.24","first-page":"1906","article-title":"Tegaserod treatment for functional dyspepsia dysmotility symptoms: results of two randomized, controlled trials","volume":"103","author":"Vakil","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"2025121301475126000_61.6.821.25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.01363.x"},{"key":"2025121301475126000_61.6.821.26","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.00900.x"},{"key":"2025121301475126000_61.6.821.27","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.128"},{"key":"2025121301475126000_61.6.821.28","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.12"},{"key":"2025121301475126000_61.6.821.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.40280.x"},{"key":"2025121301475126000_61.6.821.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812243392602"},{"key":"2025121301475126000_61.6.821.31","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90005-6"},{"key":"2025121301475126000_61.6.821.32","doi-asserted-by":"publisher","DOI":"10.1136\/gut.51.6.885"},{"key":"2025121301475126000_61.6.821.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.00225.x"},{"key":"2025121301475126000_61.6.821.34","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01236.x"},{"key":"2025121301475126000_61.6.821.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052639"},{"key":"2025121301475126000_61.6.821.36","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2007.132449"},{"key":"2025121301475126000_61.6.821.37","first-page":"154","article-title":"A Phase II placebo controlled randomized trial with tegaserod in functional dyspepsia patients with normal gastoric emptying","volume":"122","author":"Tack","year":"2002","journal-title":"Gastroenterology"},{"key":"2025121301475126000_61.6.821.38","doi-asserted-by":"publisher","DOI":"10.1007\/s11938-007-0069-0"},{"key":"2025121301475126000_61.6.821.39","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01709.x"},{"key":"2025121301475126000_61.6.821.40","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.136"},{"key":"2025121301475126000_61.6.821.41","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00655.x"},{"key":"2025121301475126000_61.6.821.42","first-page":"112","article-title":"Tegaserod withdrawal from the world market. A treatment for constipation with cardiovascluar adverse effect","volume":"17","year":"2008","journal-title":"Prescrire Int"},{"key":"2025121301475126000_61.6.821.43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2007.01059.x"},{"key":"2025121301475126000_61.6.821.44","doi-asserted-by":"crossref","first-page":"A535","DOI":"10.1016\/S0016-5085(09)62461-6","article-title":"Z-338 improves meal-induced symptoms in Functional Dyspepsia: a double-blind, randomized, placebo controlled crossover study","volume":"136","author":"Adam","year":"2009","journal-title":"Gastroenterology"},{"key":"2025121301475126000_61.6.821.45","first-page":"G228","article-title":"Influence of acute tryptophan depletion on gastric sensorimotor functions in humans","volume":"350","author":"Geeraerts","year":"2010","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2025121301475126000_61.6.821.46","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.08.020"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2011-301454","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T09:48:01Z","timestamp":1765619281000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2011-301454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,9]]},"references-count":46,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2012,5,3]]},"published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1136\/gutjnl-2011-301454"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2011-301454","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,9]]}}}